Status:
RECRUITING
Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Lead Sponsor:
Chinese PLA General Hospital
Conditions:
Gastric Cancer
Tumor Microenvironment
Eligibility:
All Genders
18-70 years
Brief Summary
The goal of this study is to analyze the tumor microenvironment (TME) in gastric cancer patients treated with combined immunotherapy and chemotherapy. The main questions it aims to answer are: * Prov...
Eligibility Criteria
Inclusion
- Non-bedridden, aged 18 to 70 years old;
- Eastern Cooperative Oncology Group (ECOG) score is 0 to 1;
- Histologically confirmed gastric adenocarcinoma with evaluable lesions based on RECIST 1.1;
- Advanced gastric cancer;
- Ready for receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab
Exclusion
- History of other malignant diseases in the last 5 years;
- Prior chemotherapy, radiotherapy or immunotherapy;
- Not receiving S-1 plus oxaliplatin chemotherapy and either nivolumab or sintilimab.
Key Trial Info
Start Date :
July 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 31 2024
Estimated Enrollment :
28 Patients enrolled
Trial Details
Trial ID
NCT06202781
Start Date
July 1 2022
End Date
July 31 2024
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100853